BioMarin Pharmaceutical Inc. (BMRN)
BMRN Stock Price Chart
Explore BioMarin Pharmaceutical Inc. interactive price chart. Choose custom timeframes to analyze BMRN price movements and trends.
BMRN Company Profile
Discover essential business fundamentals and corporate details for BioMarin Pharmaceutical Inc. (BMRN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jul 1999
Employees
3.04k
Website
https://www.biomarin.comCEO
Alexander Hardy
Description
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
BMRN Financial Timeline
Browse a chronological timeline of BioMarin Pharmaceutical Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is $0.96, while revenue estimate is $932.75m.
Earnings released on 4 May 2026
EPS came in at $0.76 falling short of the estimated $0.78 by -2.56%, while revenue for the quarter reached $766.00m , beating expectations by +1.79%.
Earnings released on 23 Feb 2026
EPS came in at -$0.24 falling short of the estimated $0.17 by -241.68%, while revenue for the quarter reached $874.57m , beating expectations by +4.90%.
Earnings released on 27 Oct 2025
EPS came in at $0.12 surpassing the estimated -$0.15 by +180.00%, while revenue for the quarter reached $776.13m , missing expectations by -5.75%.
Earnings released on 4 Aug 2025
EPS came in at $1.44 surpassing the estimated $0.86 by +67.25%, while revenue for the quarter reached $825.41m , beating expectations by +8.33%.
Earnings released on 1 May 2025
EPS came in at $1.13 surpassing the estimated $0.94 by +20.21%, while revenue for the quarter reached $745.15m , missing expectations by -2.27%.
Earnings released on 19 Feb 2025
EPS came in at $0.92 surpassing the estimated $0.54 by +70.37%, while revenue for the quarter reached $738.22m , beating expectations by +3.64%.
Earnings released on 29 Oct 2024
EPS came in at $0.91 surpassing the estimated $0.78 by +16.67%, while revenue for the quarter reached $745.74m , beating expectations by +4.69%.
Earnings released on 5 Aug 2024
EPS came in at $0.96 surpassing the estimated $0.36 by +168.31%, while revenue for the quarter reached $708.66m , beating expectations by +6.73%.
Earnings released on 24 Apr 2024
EPS came in at $0.71 surpassing the estimated $0.31 by +127.71%, while revenue for the quarter reached $648.83m , missing expectations by -0.46%.
Earnings released on 22 Feb 2024
EPS came in at $0.49 surpassing the estimated $0.44 by +11.36%, while revenue for the quarter reached $646.21m , beating expectations by +1.50%.
Earnings released on 1 Nov 2023
EPS came in at $0.46 matching the estimated $0.46, while revenue for the quarter reached $585.97m , missing expectations by -7.90%.
Earnings released on 31 Jul 2023
EPS came in at $0.54 surpassing the estimated $0.47 by +14.89%, while revenue for the quarter reached $594.60m , missing expectations by -0.11%.
Earnings released on 26 Apr 2023
EPS came in at $0.60 surpassing the estimated $0.43 by +39.53%, while revenue for the quarter reached $592.95m , missing expectations by -0.99%.
Earnings released on 27 Feb 2023
EPS came in at $0.36 surpassing the estimated -$0.07 by +614.29%, while revenue for the quarter reached $537.54m , missing expectations by -0.02%.
Earnings released on 26 Oct 2022
EPS came in at $0.45 surpassing the estimated $0.37 by +21.62%, while revenue for the quarter reached $505.34m , missing expectations by -2.53%.
Earnings released on 3 Aug 2022
EPS came in at $0.59 surpassing the estimated $0.43 by +37.21%, while revenue for the quarter reached $533.80m , beating expectations by +2.61%.
Earnings released on 27 Apr 2022
EPS came in at $0.55 surpassing the estimated $0.38 by +44.74%, while revenue for the quarter reached $519.36m , beating expectations by +1.64%.
Earnings released on 23 Feb 2022
EPS came in at $0.03 surpassing the estimated $0.03 by +0.40%, while revenue for the quarter reached $449.81m , beating expectations by +1.68%.
Earnings released on 27 Oct 2021
EPS came in at $0.18 surpassing the estimated $0.11 by +63.64%, while revenue for the quarter reached $408.74m , missing expectations by -6.37%.
Earnings released on 28 Jul 2021
EPS came in at $0.53 surpassing the estimated $0.30 by +76.67%, while revenue for the quarter reached $501.69m , beating expectations by +14.79%.
BMRN Stock Performance
Access detailed BMRN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
